pyridin-4-yl(thiophen-3-yl)methanone | 21314-82-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: pyridin-4-yl(thiophen-3-yl)methanone
• 英文别名: 3-Thienyl-4'-pyridyl ketone；pyridine-4-yl-thiophene-3-yl-methanone
• CAS: 21314-82-9
• 化学式: C₁₀H₇NOS
• 分子量: 189.238
• InChiKey: VBWNWEIBAXXUIG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  pyridin-4-yl(thiophen-3-yl)methanone 生成 4-(2-(4,5-Dihydro-1H-imidazol-2-yl)-1-thiophene-3-ylethyl)pyridine
  参考文献：
  名称：

  Oral hypoglycaemic agents

  摘要：

  式(I)的化合物，它们是可选择取代的2-(&ohgr;，&ohgr;-二芳基烷基)-4,5-二氢-1H-咪唑和2-(&ohgr;，&ohgr;-二芳基烷基)-1,4,5,6-四氢嘧啶及其与无机和有机酸的盐具有有趣的药理特性。因此，这些化合物在治疗2型糖尿病方面是有用的。

  公开号：

  US20020132812A1
• 作为产物：
  描述：

  在 (5,10,15,20-tetrakis(p-methoxyphenyl)-21H,23H-porphyrinate)cobalt(II) 、 氧气 、 sodium hydroxide 作用下， 以 1,2-二氯乙烷 、 乙腈 为溶剂， 反应 8.0h， 以72%的产率得到pyridin-4-yl(thiophen-3-yl)methanone
  参考文献：
  名称：

  光催化可控和可见光选择性氧化吡啶鎓盐

  摘要：

  这项研究提出了两种不同的方法，以空气为末端氧化剂，可光催化控制和可见光诱导的吡啶鎓的选择性氧化。这些转变的关键是选择合适的光源和光催化剂。吡啶鎓通过氧介导的环加成，质子偶联电子转移（PCET），吡啶开环和再循环成功地转化为吡咯。另一途径是吡啶鎓在钴（II）的催化下通过自由基重排/好氧氧化选择性地形成4-羰基吡啶。

  DOI：

  10.1007/s11426-020-9958-6

文献信息

• Imidazolines as efficacious glucose-dependent stimulators of insulin secretion
  作者：P Jakobsen

  DOI：10.1016/s0223-5234(03)00041-2

  日期：2003.4

  Synthesis of a series of imidazolines with glucose dependent effects on insulin exocytosis from pancreatic P-cells is reported. Regioisomers and enantionters were found to exhibit marked differences in exocytotic effects as well as different activities on the K-ATP-channel- the (R (+)) isomer of 2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-thiophene-2-ylethyl]pyridine (4a) and the (+) isomer of 2-[2-(4,5-dihydro-1H-imidazol-2-yl)-1-thiophene-3-yiethyl]pyridine (4d) were found to give a significant increase in insulin release in contrast to Findings for their enantiomers-without influence on the K-ATP-channel. The (+) isomer (4a) showed glucose dependent insulin release from P-cells at concentrations above 2.5 mM and a marked glucose lowering effect in ob/ob mice as well as in fed but not in fasted rats. (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.
• [EN] 1,3-DIAZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS ORAL HYPOGLYCAEMIC AGENTS<br/>[FR] COMPOSES 1,3 DIAZHETEROCYCLIQUES ET UTILISATION DE CES DERNIERS COMME AGENTS HYPOGLYCEMIANTS
  申请人：NOVO NORDISK AS

  公开号：WO2002038559A1

  公开（公告）日：2002-05-16

  A compound of formula (I) wherein Y is selected from the ring systems (a), (b); R?1 and R2¿ are independently phenyl, naphthyl, thienyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, quinolyl, 3-4-dihydroquinolyl, 5,6,7,8-tetrahydroquinolyl, isoquinolyl, 3,4-dihydroisoquinolyl, 5,6,7,8-tetrahydroisoquinolyl, indolyl, benzo[b]thienyl, benzimidazozyl, 5,6,7,8-tetrahydroimidazo[1,5-a]pyridyl or benzthiazolyl each of which is optionally substituted. R?3 and R5¿ are independently hydrogen, C¿1-6? alkyl or halogen or when taken together R?3 and R5¿ form an additional bond between the carbon atoms which they are attached; R¿4? is hydrogen, C1-6alkyl, arylC1-6alkyl, C1-6-C(O)- or arylC1-6alkyl-C(O)-, X is -CR?18R19¿- wherein R?18 and R19¿ are independently hydrogen or C¿1-6?alkyl; n is 0, 1 or 2. Thus, the compounds are useful in the treatment of type 2 diabetes.